Case Details

Year Initiated/Committed

2009

Year Resolved

2009

Settlement Amount

n/a

Court

U.S. District Court for the Central District of California

Docket Number

CV-09-00598

Lead State

CA

Participating States

CA

Defendant(s)

Watson Pharmaceuticals, Inc.; Par Pharmaceutical Companies, Inc; Paddock Laboratories, Inc; Solvay Pharmaceuticals, Inc.

Case Description

Plaintiff State and the FTC challenged so-called “reverse payment” agreement between Solvay Pharmaceuticals (patent holder) and Watson Pharmaceuticals, Par Pharmaceuticals and Paddock Laboratories that delayed the entry of a generic substitute for Androgel, a testosterone-replacement drug. State and the FTC alleged that Solvay, fearing the entry of lower-cost generic substitutes for Androgel, resolved patent litigation with the other three companies by making substantial payments to them, on the condition that they not enter the market with their generic version. the parties seek injunctive relief and fines of $2500 per violation under California antitrust law. Case was transferred to district court in Georgia and state did not re-file in Georgia, although the FTC did.